Filippa Nyberg
Danderyd Stockholm, Sweden
NCT Number: NCT00625521
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 2
Danderyd Stockholm, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Astion Pharma A/S
Industry
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04908280
Connective Tissue Diseases, Discoid Lupus Erythematosus
Rochester, New York, United States
View Trial DetailsNCT05362188
Connective Tissue Diseases, Discoid Lupus Erythematosus
Cairo, Egypt
View Trial DetailsNCT00708916
Connective Tissue Diseases, Discoid Lupus Erythematosus
New York, United States
View Trial DetailsNCT00691769
Alopecia, Central Centrifugal Scarring Alopecia
Winston-Salem, North Carolina, United States
View Trial Details